Sirna Therapeutics to Join the NASDAQ Biotechnology Index
News Nov 23, 2005
Sirna Therapeutics, Inc. has announced that the company was added to the NASDAQ Biotechnology Index effective at the open of the U.S. markets on 21st Nov.
"We are extremely pleased to be included among the leading biotechnology and pharmaceutical companies listed on the NASDAQ Biotechnology Index," said Howard W. Robin, Chief Executive Officer of Sirna Therapeutics.
"Our addition to this Index further supports the important achievements Sirna has made in the field of RNA interference."
"Our company is at the forefront of RNAi-based therapeutic research and development having been the first company to present human clinical trial data on a short interfering RNA compound."
"We will continue to pioneer the development of RNAi-based therapeutics and look forward to bringing this novel class of drugs to patients in need."
Launched in 1993, the NASDAQ Biotechnology Index includes securities that are classified according to the FTSE Global Classification System™ as biotechnology or pharmaceutical, and is ranked on a semi-annual basis in May and November.
All securities are listed on the NASDAQ National Market® and meet minimum requirements for market value, average daily share volume and seasoning as a public company.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.